Fox Corp Class A vs Sana Biotechnology Inc — how do they compare? Fox Corp Class A trades at $62.53 (market cap $24.58B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: Fox Corp Class A is far larger — about 21.8× Sana Biotechnology Inc's market cap, and Fox Corp Class A pays a 0.93% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FOXA | SANA | |
|---|---|---|
Market Cap | $24.58B | $1.13B |
Sector | Media | Health |
52-Week High | $76.11 | $5.92 |
52-Week Low | $48.79 | $2.68 |
Enterprise Value | $27.94B | $1.05B |
Dividend Yield | 0.93% | — |
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.30, down 1.77% on the day, with a bullish technical signal and strong quarterly earnings beats. Recent Q2 2026 EPS of $1.79 exceeded the $1.44 estimate, driven by World Cup advertising and Tubi streaming growth. The stock shows robust fundamentals with a P/E of 16.18 and net income margin of 9.84%, supported by $3.32B in operating cash flow for 2025.
The outlook is positive with a $65.33 consensus price target and 50% analyst buy ratings, though risks include reliance on sports rights and projected 2026 net cash flow decline. Upside hinges on sustained ad demand and digital segment execution amid competitive pressures.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Trailing returns across standard periods
Latest headlines on both assets
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →